Prostate News Archive
14-Aug-2006
FDA approves changes in Celsion device (Washington Business Journal)
A day after revealing plunging second-quarter sales because of a production halt on its prostate treatment device, Celsion said Friday that federal regulators have given the company the OK to resume shipments of the product. Analysis: Less is more for prostate CA? (UPI)
ANN ARBOR, Mich., Aug. 11 (UPI) -- More than half of men with low-risk prostate cancer would do better with a "watch and wait" approach to their illness, instead of receiving aggressive treatment that produces no survival benefit, says a new study. Obituaries in the news (Boston Globe)
Rufus Harley, who was billed as the world's first and only jazz bagpipe player, died Aug. 1 of prostate cancer. He was 70. Prostate cancer treatment 'too costly' (The Australian)
MEN with prostate cancer are disadvantaged as they try to access an expensive chemotherapy drug, which is listed on the Pharmaceutical Benefits Scheme only for women, a urologist says. Experimental RNA-based Drug Kills Prostate Cancer Cells Effectively And Safely (Medical News Today)
Acting as a genetic Trojan horse, an experimental RNA-based drug -- the first of its kind -- tricks its way into prostate cancer cells and then springs into action to destroy them, while leaving normal cells unarmed. [click link for full article] Drug kills prostate tumor cells (PhysOrg)
U.S. scientists have developed an experimental RNA-based drug -- the first of its kind -- that kills prostate cancer cells, without harming normal cells.
Back to Prostate News Archive
